Ponesimod (relapsing forms of multiple sclerosis (RMS))

Subject:

• Active Substance: Ponesimod
• Name: Ponvory^®
• Therapeutic area: Multiple sclerosis
• Pharmaceutical company: Janssen-Cilag GmbH

Time table:

• Start: 15.06.2021
• Final decision by G-BA: 02.12.2021

Final decision:

• Patients who did not yet receive disease modifying therapeutics or who did receive disease modifying therapeutics but have not a highly active disease:
  - No decision on additional benefit yet. G-BA updated the comparative therapy and assigned IQWiG to assess the now relevant study. The final decision on additional benefit is due in 6 months.
• Patients who received disease modifying therapeutics but still have a highly active disease: No additional benefit proved